What Remedy Robotics Makes and the N1 Status

Remedy Robotics calls the N1 System an investigational device. Remedy's news page says N1 is not available for commercial sale in any jurisdiction, and its homepage says N1's safety and effectiveness for clinical use have not been established. Neither Remedy's pages nor IEEE Spectrum reports a regulatory clearance for N1.

IEEE Spectrum describes Remedy Robotics as a 25-person business based in San Francisco. IEEE Spectrum identifies David Bell and Jake Sganga as its cofounders and says Sganga leads the technology side. Remedy describes N1 as an endovascular robotic system with teleoperation and automation built in.

Remedy says it has built the world's first artificial intelligence (AI)-powered endovascular robotic system. That is Remedy's description, rather than a finding about N1's clinical performance. Remedy's homepage presents a robotic system alongside software and an operator console. It also offers a remote demo. A demo invitation does not change the investigational and commercial-sale status Remedy prints on its pages.

Readers comparing the types of devices covered here can browse medical robots. For N1, the immediate distinction is between Remedy's reported procedures and the investigational status Remedy assigns to the device.

How the N1 System Is Described

Remedy describes N1 as a robotic system paired with software and an operator console for remote intervention. Remedy says the robotic system is built to handle a procedure from end to end. It describes the console as providing AI-native visualization and machine learning (ML)-based tool control, designed for operation from nearby or as far as 5,000 miles away.

IEEE Spectrum reports that N1 uses a steerable catheter without a guide wire. According to IEEE Spectrum, an external robotic arm advances the catheter while small wires move its leading tip. IEEE Spectrum's illustration describes a rail with seven modules that feed the catheter.

IEEE Spectrum reports that a computer-vision algorithm tracks markings on the catheter to follow its rotation inside the body. The article says Remedy's software converts an operator's intended direction into a matching movement. IEEE Spectrum also reports that Sganga showed its writer a computed tomography (CT) scan overlaid on an X-ray feed.

IEEE Spectrum reports that Remedy targets a round-trip latency of no more than 150 milliseconds and says the system pauses surgical action above that threshold. Bell and Sganga told IEEE Spectrum they had operated the system across the Pacific using a mobile hotspot. Those are reported design details and a statement from Remedy's cofounders, rather than published clinical outcomes.

IEEE Spectrum says its writer practiced on a prototype console at Remedy's office using silicone tubing in a plastic container. The article describes an Xbox controller in the writer's hand and says the surgical robot was real. That account describes the writer's demonstration setup. Remedy says N1's safety and effectiveness for clinical use have not been established.

Remedy Robotics Milestones at a Glance

Remedy's homepage and news page record development announcements from 2022 through November 2026. IEEE Spectrum gives a separate account of human procedures and planned trials. Each dated entry below retains the source's wording or attribution. An announcement of a procedure or partnership does not alter the investigational labeling on Remedy's pages.

The sources differ on the date of first human use. Remedy's homepage labels a first-in-human (FIH) study as 2024, and Remedy's news page dates its first-in-human procedures announcement to December 2024. IEEE Spectrum describes Remedy's first test in human patients in Toronto in September 2025.

DateMilestoneSource
2022Remedy says it completed its first in vivo trials, including remote drives from 8,000 miles away.Remedy news page
2023-12-01Remedy says its system was integrated into a clinical environment for the first time.Remedy news page
2024Remedy's homepage labels entirely robotic neurointerventional procedures at a Toronto hospital with Dr. Vitor Mendes Pereira as a first-in-human study.Remedy homepage
2024-12-10Remedy announced that it had completed its first-in-human clinical procedures.Remedy news page
September 2025IEEE Spectrum reports that Bell went to Toronto for what it calls Remedy's first test in human patients. The article says ten patients had consented to nonemergency procedures.IEEE Spectrum
2025-10-24Remedy announced what it calls the world's first fully remote neurointerventional procedures.Remedy news page
2025-10-24Remedy announced a partnership with the Australian Stroke Alliance to accelerate N1 deployment in Australia.Remedy news page
2025-10-24Remedy announced that SVIN Mission Thrombectomy had selected Remedy as its exclusive robotics partner.Remedy news page
2025Remedy's homepage labels entirely remotely controlled neurointerventional procedures at a Toronto hospital as a first-in-human study.Remedy homepage
2026-11-09Remedy announced a $62 million Series B led by DCVC, with other investors.Remedy news page

What Is Not Established

Remedy says N1's safety and effectiveness for clinical use have not been established. Neither Remedy's homepage, its news page nor IEEE Spectrum reports a regulatory clearance for N1 in the pages read on November 17, 2026. Silence in those sources does not establish what may exist elsewhere.

IEEE Spectrum reports that Remedy's upcoming trials will begin with on-site elective procedures. Bell told IEEE Spectrum that the University of California system would host clinical studies within a year of the article's November 2026 publication. IEEE Spectrum reports that Remedy expects to expand to remote procedures in Australia or within that university system near the end of 2027.

IEEE Spectrum quotes information systems researcher Mike Teodorescu saying experts usually consider 100 milliseconds a safe latency threshold. The article reports his concern that network infrastructure in many rural communities and countries struggles to meet that figure. Teodorescu's quoted figure is 100 milliseconds, while IEEE Spectrum reports a 150-millisecond target for Remedy.

IEEE Spectrum quotes Bell drawing a boundary around what the system's handling could show: "Smoothness and precision are not clinical outcomes. Neither is a surgeon's ergonomics." IEEE Spectrum also reports that planned trials will examine how doctors learn the technique and how staff set up draping and tools. Readers looking for the broader regulatory and hospital-use context can read how surgical robots are cleared and credentialed.

Recent News

The two most recent dated items are IEEE Spectrum's November 2026 feature and Remedy's Series B announcement. IEEE Spectrum discusses the planned sequence from on-site trials to later remote procedures. Remedy's funding announcement names the investors but does not change the investigational labeling on its pages.

Who This Is Not For and What Would Change the Assessment

Readers seeking treatment decisions should not rely on coverage of N1. Remedy says N1's safety and effectiveness for clinical use have not been established.

Remedy says N1 is not available for commercial sale in any jurisdiction, even though its homepage offers a remote demo. A demo request and commercial availability are separate matters under Remedy's own labeling.

The assessment would change if a regulator clears N1 or clinical-trial results are published. Until then, Remedy's procedure announcements and IEEE Spectrum's account of planned trials document reported progress, without establishing clinical benefit. Readers following that progress can use Remedy's dated news page for its announcements while keeping Remedy's investigational labeling in view.

Bottom Line

Remedy says N1 is investigational and is not available for commercial sale in any jurisdiction, and that its safety and effectiveness for clinical use have not been established. Neither Remedy nor IEEE Spectrum reports a regulatory clearance for N1. Remedy and IEEE Spectrum report Toronto procedures, funding and planned trials, which show development progress rather than established clinical benefit. The assessment applies to readers tracking medical-robot news, and a regulatory clearance or published clinical-trial results would change it.

For context on the distinction between a surgical robot's development and its use in hospitals, read how surgical robots are cleared and credentialed.

FAQs

Is Remedy Robotics' N1 approved or for sale?

Neither Remedy's pages nor IEEE Spectrum reports a regulatory clearance for N1. Remedy says N1 is an investigational device and is not available for commercial sale in any jurisdiction, and that its safety and effectiveness for clinical use have not been established. Those source statements do not prove that a clearance cannot exist outside the pages read.

Who makes the N1 and where is Remedy Robotics based?

Remedy Robotics makes the N1 endovascular robotic system. IEEE Spectrum reports that Remedy is based in San Francisco and was cofounded by David Bell and Jake Sganga.

How much funding has Remedy Robotics raised?

Remedy announced a $62 million Series B on November 9, 2026. Remedy's homepage names DCVC as the lead investor, with other investors. That figure describes the announced funding round, not a verified total of all funding Remedy has raised.

Where has Remedy said N1 procedures took place?

Remedy identifies a hospital in Toronto for its reported entirely robotic and remotely controlled neurointerventional procedures. Remedy's homepage dates the first-in-human study for the entirely robotic procedures to 2024 and labels the remote-procedure study as 2025. IEEE Spectrum separately describes what it calls Remedy's first test in human patients in Toronto in September 2025.

What does Remedy Robotics plan next for N1?

IEEE Spectrum reports that Remedy plans to begin clinical trials with on-site elective procedures before expanding to remote procedures in Australia or within the University of California system near the end of 2027. Those are reported plans, not completed trials or established clinical outcomes.

Can this page guide treatment decisions?

No. This page reports statements by Remedy Robotics and IEEE Spectrum and provides general information, not medical advice. This page does not offer treatment advice.

Primary Sources